Extended dosing of monoclonal antibodies in multiple sclerosis

Over the past two decades, treatment options for patients with multiple sclerosis (MS) have increased exponentially. In the current therapeutic landscape, no evidence of MS disease activity is within reach in many of our patients. Minimizing risks of complications, improving treatment convenience, and decreasing health care costs are goals that are yet to be reached. One way to optimize MS therapy is to implement personalized or extended interval dosing. Monoclonal antibodies are suitable candidates for personalized dosing (by therapeutic drug monitoring) or extended interval dosing. An increasing number of studies are performed and underway reporting on altered dosing intervals of anti-alpha(4)beta(1)-integrin treatment (natalizumab) and anti-CD20 treatment (ocrelizumab, rituximab, and ofatumumab) in MS. In this review, current available evidence regarding personalized and extended interval dosing of monoclonal antibodies in MS is discussed with recommendations for future research and clinical practice.

Automated summary

Over the past two decades, there has been a significant increase in treatment options for patients with multiple sclerosis (MS). Personalized or extended interval dosing, particularly using monoclonal antibodies, is being increasingly explored as a way to optimize MS therapy. Studies on altered dosing intervals of monoclonal antibodies in MS treatment are ongoing and provide promising insights for future research and clinical practice.